Company intelligence / Profile preview

Protibea Therapeutics Inc.

Georgetown, Texas, United States

Ownership: Private
Development stage: Preclinical

Overview

Lead product has been dosed in 200+ patients for up to one year in early phase trials. The product has a three-pronged mechanism of action: correcting chronic unproductive inflammation by normalizing elevated levels of IL-1b, IL-6, and TNF-a; correcting insulin resistance; and stimulating autophagy important for microglial function.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small molecules (specifically 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone, referred to as BEA, formulated as an aqueous suspension for injection)
Industry: Biotech

Drug pipeline

1 asset

Immune Regulating Hormone

Pre-clinical

Indications: Alzheimer's Disease

Beyond the preview

Go deeper on Protibea Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protibea Therapeutics Inc..

Explore the full profile